SOAT1 and neoplasm: Therefore, disruption of aberrant STAT activation in tumours, which typically depends on deregulation of specific upstream tyrosine kinases, has been proposed as a valid molecular target for cancer therapy (Bowman et al, 2000; Turkson and Jove, 2000; Bromberg, 2001, 2002; Buettner et al, 2002).